Omics profiling of CDK4/6 inhibitors reveals functionally important secondary targets of abemaciclib (Conference Presentation)

Caitlin Mills; Marc Hafner; Kartik Subramanian; Chen Chen; Sarah Boswell; Robert Everley; Dejan Juric; Peter K. Sorger

doi:10.1117/12.2293203

14 March 2018 Omics profiling of CDK4/6 inhibitors reveals functionally important secondary targets of abemaciclib (Conference Presentation)

Caitlin Mills, Marc Hafner, Kartik Subramanian, Chen Chen, Sarah Boswell, Robert Everley, Dejan Juric, Peter K. Sorger

Author Affiliations +

Proceedings Volume 10475, Visualizing and Quantifying Drug Distribution in Tissue II; 104750F (2018) https://doi.org/10.1117/12.2293203
Event: SPIE BiOS, 2018, San Francisco, California, United States

Abstract

The recent introduction of small molecule inhibitors of cyclin-dependent kinases (CDK) 4/6 to the clinic has improved the treatment of hormone receptor positive breast cancer, and shown promise in other malignancies. The three clinically-used CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, are reported to be broadly similar although recent data suggest that abemaciclib has distinct single-agent activity in patients and a unique toxicity profile. Key questions are: How do these drugs differ at the molecular level? Should such differences inform their use in the clinic? Can these three agents be used interchangeably or should patient stratification differ between them? We started to address these questions by characterizing the spectrum of kinases inhibited by palbociclib, ribociclib, and abemaciclib, and the functional consequences of their inhibition in cell lines using multiple methods. First, in vitro biochemical profiling of the CDK4/6 inhibitors confirmed abemaciclib to be more potent on target, but less selective than either palbociclib or ribociclib. We used profiling by mRNA sequencing to capture differences in transcriptional response; mass spectrometry-based proteomics to infer changes in kinase activity following treatment, and imaging-based dose response, and immunofluorescence assays to characterize the phenotypic responses of breast cancer cell lines to the three CDK4/6 inhibitors. We propose that multi-omic approaches are required to fully elucidate the spectrum of targets relevant to drug mechanisms of action in cells, and we expect such understanding to inform clinical use of these drugs.

Conference Presentation

Citation Download Citation

Caitlin Mills, Marc Hafner, Kartik Subramanian, Chen Chen, Sarah Boswell, Robert Everley, Dejan Juric, and Peter K. Sorger "Omics profiling of CDK4/6 inhibitors reveals functionally important secondary targets of abemaciclib (Conference Presentation)", Proc. SPIE 10475, Visualizing and Quantifying Drug Distribution in Tissue II, 104750F (14 March 2018); https://doi.org/10.1117/12.2293203

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available